, Volume 2, Issue 1, pp 1-6
Date: 18 Dec 2010

Resolving the Negative Data Publication Dilemma in Translational Stroke Research

This is an excerpt from the content

“Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning” ∼∼Albert Einstein (physicist, Nobel Prize in 1921. 1879–1955).

Stroke Therapies: The Continuing Challenge

The development of new treatments for stroke remains a formidable challenge as emphasized in the article by Frank Sharp and colleagues [1]. However, with the recent advances in genomic and proteomic profiling [24], in vitro screening methodologies [57], predictive animal models [812], and a greater understanding of the complexity of processes and mechanisms involved in cellular degeneration and behavioral deficits following a stroke [13, 14], we now have the basic tools in our repertoire to develop and systematically test new candidates in a preclinical translational setting. Moreover, with more sophisticated adaptive clinical trial design [1518], therapy can be targeted to specific stroke patient populations to ensure some extent of efficacy, rather than complete failure. If